|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MS4A8 |
Gene summary for MS4A8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MS4A8 | Gene ID | 83661 |
| Gene name | membrane spanning 4-domains A8 | |
| Gene Alias | 4SPAN4 | |
| Cytomap | 11q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9BY19 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83661 | MS4A8 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.87e-12 | 5.22e-01 | -0.1808 |
| 83661 | MS4A8 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.15e-08 | 3.35e-01 | -0.0811 |
| 83661 | MS4A8 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.75e-06 | 3.52e-01 | -0.1088 |
| 83661 | MS4A8 | HTA11_347_2000001011 | Human | Colorectum | AD | 9.89e-13 | 5.08e-01 | -0.1954 |
| 83661 | MS4A8 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.31e-06 | 1.11e+00 | -0.2602 |
| 83661 | MS4A8 | HTA11_83_2000001011 | Human | Colorectum | SER | 8.90e-05 | 3.96e-01 | -0.1526 |
| 83661 | MS4A8 | AEH-subject3 | Human | Endometrium | AEH | 1.37e-30 | 7.69e-01 | -0.2576 |
| 83661 | MS4A8 | AEH-subject4 | Human | Endometrium | AEH | 3.96e-04 | 3.20e-01 | -0.2657 |
| 83661 | MS4A8 | EEC-subject2 | Human | Endometrium | EEC | 1.94e-02 | 2.81e-01 | -0.2607 |
| 83661 | MS4A8 | EEC-subject4 | Human | Endometrium | EEC | 5.56e-12 | 5.43e-01 | -0.2571 |
| 83661 | MS4A8 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 7.51e-05 | 3.57e-01 | -0.1916 |
| 83661 | MS4A8 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 4.13e-12 | 4.04e-01 | -0.1269 |
| 83661 | MS4A8 | HCC2_Meng | Human | Liver | HCC | 2.48e-31 | 2.98e-01 | 0.0107 |
| 83661 | MS4A8 | S027 | Human | Liver | HCC | 3.69e-08 | 5.31e-01 | 0.2446 |
| 83661 | MS4A8 | S028 | Human | Liver | HCC | 2.88e-14 | 5.15e-01 | 0.2503 |
| 83661 | MS4A8 | S029 | Human | Liver | HCC | 2.25e-19 | 6.23e-01 | 0.2581 |
| 83661 | MS4A8 | HTA12-23-1 | Human | Pancreas | PDAC | 1.39e-02 | 5.57e-01 | 0.3405 |
| 83661 | MS4A8 | HTA12-26-1 | Human | Pancreas | PDAC | 2.05e-12 | 6.35e-01 | 0.3728 |
| 83661 | MS4A8 | HTA12-29-1 | Human | Pancreas | PDAC | 7.94e-32 | 7.23e-01 | 0.3722 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MS4A8 | SNV | Missense_Mutation | c.110N>T | p.Pro37Leu | p.P37L | Q9BY19 | protein_coding | deleterious(0) | possibly_damaging(0.823) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| MS4A8 | SNV | Missense_Mutation | c.473N>T | p.Thr158Ile | p.T158I | Q9BY19 | protein_coding | tolerated(0.2) | benign(0.131) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| MS4A8 | SNV | Missense_Mutation | c.737N>A | p.Ile246Asn | p.I246N | Q9BY19 | protein_coding | deleterious(0.01) | benign(0.084) | TCGA-E2-A1B0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| MS4A8 | SNV | Missense_Mutation | rs776863093 | c.26N>T | p.Pro9Leu | p.P9L | Q9BY19 | protein_coding | deleterious(0.02) | possibly_damaging(0.832) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MS4A8 | SNV | Missense_Mutation | rs375232214 | c.164N>T | p.Ser55Leu | p.S55L | Q9BY19 | protein_coding | tolerated(0.11) | benign(0.052) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MS4A8 | SNV | Missense_Mutation | c.275N>T | p.Thr92Met | p.T92M | Q9BY19 | protein_coding | tolerated(0.09) | possibly_damaging(0.718) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MS4A8 | SNV | Missense_Mutation | novel | c.553N>C | p.Ser185Pro | p.S185P | Q9BY19 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MS4A8 | SNV | Missense_Mutation | c.8N>T | p.Ser3Leu | p.S3L | Q9BY19 | protein_coding | tolerated(0.14) | benign(0) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MS4A8 | SNV | Missense_Mutation | c.8C>T | p.Ser3Leu | p.S3L | Q9BY19 | protein_coding | tolerated(0.14) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| MS4A8 | SNV | Missense_Mutation | rs758725009 | c.548N>T | p.Ala183Val | p.A183V | Q9BY19 | protein_coding | tolerated(0.09) | benign(0.253) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |